Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...

Journavx (suzetrigine) is said to reduce pin by "targeting a pain-signaling pathway involving sodium channels in the ...